(1S,2R)-2-(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (1S,2R)-2-(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
• 化学式: C₁₇H₁₉NO
• 分子量: 253.344
• InChiKey: QCNNDDJZXNZNPP-IAGOWNOFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1S,2R)-2-(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine 在 三溴化硼 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-[(1S,2R)-2-(4-Hydroxy-phenyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-2,2-diphenyl-acetamide
  参考文献：
  名称：

  Inhibitors of Acyl CoA:Cholesterol Acyltransferase

  摘要：

  Conformational restriction of previously disclosed acyclic diphenylethyl)diphenylacetamides led to the discovery of several potent inhibitors of acyl CoA:cholesterol acyltransferase (ACAT). cis-[2-(4-Hydroxyphenyl)-1-indanyl]diphenylacetamide (4a) was the mo st potent ACAT inhibitor identified (IC50 = 0.04 mu M in an in vitro rat hepatic microsomal ACAT assay, ED(50) = 0.72 mg/kg/day in cholesterol-fed hamsters).

  DOI：

  10.1021/jm950833d
• 作为产物：
  描述：

  N-diphenylphosphoryl-2-(4-methoxyphenyl)-3,4-dihydro-2H-naphthalen-1-imine 在 盐酸 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 0.17h， 生成 (1S,2R)-2-(4-methoxyphenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
  参考文献：
  名称：

  Inhibitors of Acyl CoA:Cholesterol Acyltransferase

  摘要：

  Conformational restriction of previously disclosed acyclic diphenylethyl)diphenylacetamides led to the discovery of several potent inhibitors of acyl CoA:cholesterol acyltransferase (ACAT). cis-[2-(4-Hydroxyphenyl)-1-indanyl]diphenylacetamide (4a) was the mo st potent ACAT inhibitor identified (IC50 = 0.04 mu M in an in vitro rat hepatic microsomal ACAT assay, ED(50) = 0.72 mg/kg/day in cholesterol-fed hamsters).

  DOI：

  10.1021/jm950833d

文献信息

• Bicyclic amides as inhibitors of acyl-coenzyme A: cholesterol acyl
  申请人：Schering Corporation

  公开号：US05416118A1

  公开（公告）日：1995-05-16

  Novel bicyclic amides of the formula ##STR1## wherein Ar.sup.1 and Ar.sup.2 are phenyl, R.sup.2 -substituted phenyl, heteroaryl or R.sup.2 -substituted heteroaryl, wherein R.sup.2 is 1 to 3 substituents independently selected from the group consisting of halogeno, hydroxy, lower alkyl, lower alkoxy, nitro, amino, lower alkylamino and lower dialkylamino; X, Y and Z are --CH.sub.2 --, --CH(alkyl)--, --C(alkyl).sub.2 --, --NH--, --N(alkyl)--, --O-- or --SO.sub.r, wherein r is 0, 1 or 2, and m, n and p are 0 or 1; R.sup.1 is an alkyl chain of 1 to 25 carbon atoms; an alkyl chain substituted by one or more optionally substituted phenyl or heteroaryl groups; an alkyl chain --O--, --SO.sub.r, phenylene, R.sup.2 -substituted phenylene, heteroarylene or R.sup.2 -substituted heteroarylene groups; an interrupted alkyl chain substituted by one or more optionally substituted phenyl or heteroaryl groups; an alkyl chain of 4 to 25 carbon atoms, interrupted by one or more --NH--, --C(O)-- or --N(lower alkyl)-- groups; an interrupted alkyl chain of 4 to 25 carbon atoms substituted by one or more phenyl, R.sup.2 -substituted phenyl, heteroaryl or R.sup.2 -substituted heteroaryl groups; a diphenylamino group; a di-(R.sup.2 -substituted phenyl)amino group; a diheteroarylamino group; or a di-(R.sup.2 -substituted heteroaryl)amino group; or a pharmaceutically acceptable salt thereof, useful in the treatment of artherosclerosis are disclosed.

  公开了式子为##STR1##的新颖双环酰胺，其中Ar.sup.1和Ar.sup.2是苯基，R.sup.2-取代苯基，杂环基或R.sup.2-取代的杂环基，其中R.sup.2是1到3个取自卤素，羟基，低级烷基，低级烷氧基，硝基，氨基，低级烷基氨基和低级双烷基氨基的官能团；X，Y和Z是--CH.sub.2--，--CH(烷基)--，--C(烷基).sub.2--，--NH--，--N(烷基)--，--O--或--SO.sub.r，其中r为0，1或2，而m，n和p为0或1；R.sup.1是1到25个碳原子的烷基链；一个由一个或多个可选取代的苯基或杂环基取代的烷基链；一个烷基链--O--，--SO.sub.r，苯基，R.sup.2-取代苯基，杂环基或R.sup.2-取代杂环基；一个被一个或多个可选取代的苯基或杂环基取代的中断烷基链；一个由一个或多个--NH--，--C(O)--或--N(低级烷基)--组成的4到25个碳原子的中断烷基链；一个由一个或多个苯基，R.sup.2-取代苯基，杂环基或R.sup.2-取代杂环基取代的4到25个碳原子的中断烷基链；一个二苯胺基团；一个二-(R.sup.2-取代苯基)氨基团；一个二杂环芳基氨基团；或一个二-(R.sup.2-取代杂环芳基)氨基团；或其药学上可接受的盐，用于治疗动脉粥样硬化。
• Inhibitors of Acyl CoA:Cholesterol Acyltransferase
  作者：Wayne Vaccaro、Cindy Amore、Joel Berger、Robert Burrier、John Clader、Harry Davis、Martin Domalski、Tom Fevig、Brian Salisbury、Rosy Sher

  DOI：10.1021/jm950833d

  日期：1996.1.1

  Conformational restriction of previously disclosed acyclic diphenylethyl)diphenylacetamides led to the discovery of several potent inhibitors of acyl CoA:cholesterol acyltransferase (ACAT). cis-[2-(4-Hydroxyphenyl)-1-indanyl]diphenylacetamide (4a) was the mo st potent ACAT inhibitor identified (IC50 = 0.04 mu M in an in vitro rat hepatic microsomal ACAT assay, ED(50) = 0.72 mg/kg/day in cholesterol-fed hamsters).